tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Cogent Biosciences (COGT), BridgeBio Pharma (BBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGTResearch Report) and BridgeBio Pharma (BBIOResearch Report) with bullish sentiments.

Cogent Biosciences (COGT)

In a report released today, Michael King from H.C. Wainwright maintained a Buy rating on Cogent Biosciences, with a price target of $31.00. The company’s shares closed last Tuesday at $5.54, close to its 52-week low of $5.15.

According to TipRanks.com, King is a 4-star analyst with an average return of 7.5% and a 42.0% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cogent Biosciences with a $22.50 average price target, a 322.1% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.

See the top stocks recommended by analysts >>

BridgeBio Pharma (BBIO)

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on BridgeBio Pharma, with a price target of $22.00. The company’s shares closed last Tuesday at $8.51, close to its 52-week low of $7.10.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -33.9% and a 17.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Aquestive Therapeutics, and Vallon Pharmaceuticals.

Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $24.25, a 192.5% upside from current levels. In a report issued on March 1, Bank of America Securities also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COGT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed